Imagion Biosystems (ASX: IBX) is the company behind MagSense, a revolutionary imaging agent. The company has just made an IND submission to the US FDA and plans to take MagSense into a Phase 2 clinical trial for HER2+ breast cancer once an answer from the regulator is received and this could be as early as Q1 in 2026. A $2bn TAM awaits The market for cancer diagnostics is a US$100bn market. […]